Wird geladen...
The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemia
Antibody–drug conjugates (ADCs) are likely to make a significant contribution in the treatment of acute lymphoblastic leukemia (ALL) by combining the cytotoxicity of chemotherapy with the specificity of monoclonal antibodies. CD22, an endocytic receptor expressed by the majority of B cells, is an ex...
Gespeichert in:
| Veröffentlicht in: | Ther Adv Hematol |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
SAGE Publications
2015
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4556970/ https://ncbi.nlm.nih.gov/pubmed/26425338 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620715596715 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|